发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC SFJ制药公司将开展辉瑞达科米替尼治疗一线晚期NSCLC的III期临床试验
Pharmadeals Review Pub Date : 2012-09-26 DOI: 10.3833/PDR.V2012I9.1809
Heather Cartwright
{"title":"SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1809","DOIUrl":"https://doi.org/10.3833/PDR.V2012I9.1809","url":null,"abstract":"SFJ Pharmaceuticals has formed its second collaborative development agreement with Pfizer, this time to conduct a Phase III trial to evaluate Pfizer’s pan-Her (pan-human epidermal growth factor receptor) inhibitor dacomitinib (PF-00299804) as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating EGFR (epidermal growth factor receptor) mutations. The NSCLC market continues to move towards molecular-targeted therapies used alongside companion diagnostics to guide treatment decisions.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73251124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST 辉瑞为VLST提供临床期癌症抗体
Pharmadeals Review Pub Date : 2012-09-26 DOI: 10.3833/pdr.v2012i9.1807
Heather Cartwright
{"title":"Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST","authors":"Heather Cartwright","doi":"10.3833/pdr.v2012i9.1807","DOIUrl":"https://doi.org/10.3833/pdr.v2012i9.1807","url":null,"abstract":"Seattle-based biotech VLST has moved into oncology and the clinical development arena by licensing CP-870,893, an anti-CD40 monoclonal antibody, from Pfizer. The drug has completed five Phase I trials and VLST will be responsible for advancing it into Phase II development. As part of the deal, Pfizer has acquired a 5% equity stake in VLST and will retain co-exclusive rights to the drug in the oncology vaccine field. The agreement represents the latest example of Pfizer’s portfolio management strategy in oncology.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84604896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option Vascular Pharma完成1600万美元A轮融资并授予Janssen Biotech收购选择权
Pharmadeals Review Pub Date : 2012-09-26 DOI: 10.3833/PDR.V2012I9.1810
Heather Cartwright
{"title":"Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I9.1810","DOIUrl":"https://doi.org/10.3833/PDR.V2012I9.1810","url":null,"abstract":"Vascular Pharmaceuticals has signed an agreement with Johnson & Johnson’s Janssen Biotech that grants Janssen the exclusive right to acquire the North Carolina-based company following the completion of a planned Phase II study of its lead monoclonal antibody drug candidate VPI-2690B for diabetic nephropathy. The deal follows the successful completion by Vascular Pharma of a US$16 M Series A equity financing, the company’s first institutional round of funding, which it hopes will be sufficient to advance preclinical-stage VPI-2690B through Phase II.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78161591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks 阿斯利康在研发受挫后签署两项协议加强产品线
Pharmadeals Review Pub Date : 2012-09-01 DOI: 10.3833/PDR.V2012I1.1652
Heather Cartwright
{"title":"AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I1.1652","DOIUrl":"https://doi.org/10.3833/PDR.V2012I1.1652","url":null,"abstract":"After suffering development setbacks with regard to two of its late-stage drug candidates, AstraZeneca has signed separate deals with two Asian pharmaceutical companies to help bolster its sparse pipeline. In a deal potentially worth more than US$140 M, AstraZeneca has licensed rights from Hutchison MediPharma to co-develop and commercialise volitinib, a preclinical c-Met receptor tyrosine kinase inhibitor being developed for cancer. The company has also obtained an option to acquire the type 2 diabetes assets of Astellas Pharma’s Prosidion subsidiary, Phase II PSN821 and preclinical-stage PSN842.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"108 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75807424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pfizer Collaborates with Nodality to Streamline Autoimmune Disease Drug Development 辉瑞与Nodality合作简化自身免疫性疾病药物开发
Pharmadeals Review Pub Date : 2012-08-15 DOI: 10.3833/PDR.V2012I8.1790
Heather Cartwright
{"title":"Pfizer Collaborates with Nodality to Streamline Autoimmune Disease Drug Development","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I8.1790","DOIUrl":"https://doi.org/10.3833/PDR.V2012I8.1790","url":null,"abstract":"Pfizer has formed a multiyear collaboration with Nodality to use the latter’s single cell network profiling (SCNP) technology as a tool to streamline the development of new compounds for autoimmune diseases, beginning with lupus. Pfizer also has the option to use Nodality's technology, which was licensed from Stanford University, to develop novel companion diagnostics. Pfizer Venture Investments has been an investor in Nodality since 2008.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72610192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intrexon and Synthetic Biologics Collaborate Again Intrexon和合成生物制剂再次合作
Pharmadeals Review Pub Date : 2012-08-14 DOI: 10.3833/PDR.V2012I8.1789
Heather Cartwright
{"title":"Intrexon and Synthetic Biologics Collaborate Again","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I8.1789","DOIUrl":"https://doi.org/10.3833/PDR.V2012I8.1789","url":null,"abstract":"Synthetic Biologics has partnered with Intrexon for a second time to develop and commercialise monoclonal antibodies for three undisclosed infectious disease indications utilising Intrexon's synthetic biology technologies. In return, Intrexon will receive 3.6 million shares of Synthetic common stock, bringing its ownership position in the company to approximately 18%. Intrexon also stands to gain milestone payments and royalties and the collaboration may be expanded to include up to five additional infectious disease indications.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83741792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
UCB Accesses Brazilian Market by Acquiring Majority Stake in Meizler Biopharma UCB通过收购Meizler Biopharma的多数股权进入巴西市场
Pharmadeals Review Pub Date : 2012-08-06 DOI: 10.3833/PDR.V2012I6.1751
Heather Cartwright
{"title":"UCB Accesses Brazilian Market by Acquiring Majority Stake in Meizler Biopharma","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1751","DOIUrl":"https://doi.org/10.3833/PDR.V2012I6.1751","url":null,"abstract":"UCB Pharma has agreed to acquire a 51% majority stake in privately held Meizler Biopharma in order to make a direct entry into the Brazilian pharmaceutical market. Although the specific financial details of the transaction were not disclosed, Meizler’s owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% in the future. The deal is the latest example of a global pharmaceutical company targeting Brazil for expansion.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85721332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline 勃林格殷格翰将II期抗炎药加入其呼吸道疾病产品线
Pharmadeals Review Pub Date : 2012-07-31 DOI: 10.3833/PDR.V2012I7.1786
Heather Cartwright
{"title":"Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I7.1786","DOIUrl":"https://doi.org/10.3833/PDR.V2012I7.1786","url":null,"abstract":"Boehringer Ingelheim has acquired global rights to Funxional Therapeutics’ Phase II oral anti-inflammatory drug FX125L, a potential first-in-class somatotaxin, as well as a somatotaxin development programme. The deal will strengthen Boehringer Ingelheim’s respiratory pipeline, which includes the long-acting beta agonist olodaterol and nintedanib for idiopathic pulmonary fibrosis. The company already markets the blockbuster COPD therapy Spiriva® (tiotropium bromide).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85331978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement Genmab与Janssen Biotech达成协议，进一步验证其DuoBody™技术
Pharmadeals Review Pub Date : 2012-07-25 DOI: 10.3833/PDR.V2012I7.1784
Heather Cartwright
{"title":"Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I7.1784","DOIUrl":"https://doi.org/10.3833/PDR.V2012I7.1784","url":null,"abstract":"Genmab has made further progress with its DuoBody™ technology platform by agreeing to collaborate with Johnson & Johnson’s Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront plus potential milestone and licence payments of up to US$175 M for each product successfully developed from the collaboration as well as royalties on sales of any commercialised products. Amgen’s US$1.16 B acquisition of Micromet in March 2012 fuelled industry interest in bispecific antibody technologies.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80684948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reckitt Benckiser Ventures into Vitamins, Minerals and Supplements Market with Schiff Nutrition Purchase 利洁时收购希夫营养品，进军维生素、矿物质和补充剂市场
Pharmadeals Review Pub Date : 2012-07-12 DOI: 10.3833/PDR.V2012I12.1857
Heather Cartwright
{"title":"Reckitt Benckiser Ventures into Vitamins, Minerals and Supplements Market with Schiff Nutrition Purchase","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I12.1857","DOIUrl":"https://doi.org/10.3833/PDR.V2012I12.1857","url":null,"abstract":"In a surprise move, Reckitt Benckiser (RB) has outbid Bayer with an offer to acquire Schiff Nutrition, a US-based provider of branded vitamins, nutritional supplements and nutrition bars, for US$1.4 B. The acquisition, which has been approved by the Board of Directors of Schiff, will provide RB with a significant entry into the US$30 B vitamins and nutrition supplements market with the addition of brands such as MegaRed® for cardiovascular health, Move Free® to preserve and repair cartilage, Airborne® immune support products and Schiff Vitamins®.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2012-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89976812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信